在乳腺癌患者的同时服用药物,并发症和生存率
Elise Dumas1,2,3, Beatriz Grandal Rejo1, Paul Gougis1
1Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Université Paris Cité, F-75005, Paris, France.
Nature communications
|April 5, 2024
概括
许多乳腺癌患者使用非癌症药物. 这项研究确定了与改善或恶化乳腺癌存活率相关的特定药物,提供了新的研究假设.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 乳腺癌患者中很大一部分 (30-70%) 已经存在慢性疾病.
- 超过一半的乳腺癌患者在诊断时长期服用非癌症药物.
- 新出现的证据表明,非癌症药物可能会影响乳腺癌的结果.
研究的目的:
- 研究诊断时非癌症药物使用与乳腺癌存活率之间的关联.
- 确定可能影响整体存活率和无病存活率的特定药物.
- 为了产生对可能影响乳腺癌进展的药物的假设.
主要方法:
- 全国范围的队列研究包括235,368名新诊断为非转移性乳腺癌的法国妇女.
- 分析使用288种不同的药物与生存结果之间的关联.
- 利用交互式在线平台进行全面的成果传播.
主要成果:
- 八种药物与总体或无疾病生存率有积极关联:拉贝普拉,阿尔维林,阿特诺洛尔,西姆瓦斯塔丁,罗斯瓦斯塔丁,埃斯特里奥尔,诺梅格斯特罗尔和高血糖.
- 八种药物与总体或无疾病存活率有负相关性:铁,普雷迪尼索隆,碳醇,普里斯胺,奥克萨泽帕姆,阿尔普拉佐拉姆,氧和米安塞林.
结论:
- 在乳腺癌诊断中使用的特定非癌症药物显示与患者存活率的关联.
- 这些发现为进一步研究药物诱导的乳腺癌演变调节的研究提供了基础.
- 一个交互式平台为产生假设提供了关于药物生存关联的详细见解.
更多相关视频
04:57Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
10.2K
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
10.9K
相关概念视频
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:20Comparing the Survival Analysis of Two or More Groups
181
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
181
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:24Kaplan-Meier Approach
136
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
136
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K